Catherine M. Kelly

7.9k citations

149 papers · 3.6k indexed · 2 hit papers · h-index 32

Oncology top 1%
Cancer Research top 1%
Pulmonary and Respiratory Medicine top 2%
Molecular Biology
Genetics top 5%

Co-authors: Lajos Pusztai Melanie Smith Giuseppe Viale Minh Duong-Hua David N. Juurlink Tara Gomes Lawrence Paszat K. I. Pritchard
Topics: Breast Cancer Treatment Studies (33 papers)Advanced Breast Cancer Therapies (28 papers)HER2/EGFR in Cancer Research (28 papers)
Cited by: Cancer Research Oncology Pulmonary and Respiratory Medicine
Journals: Journal of Clinical Oncology Diabetes Care JNCI Journal of the National Cancer Institute
Partner nations: Ireland United States United Kingdom

In The Last Decade

Catherine M. Kelly

144 papers receiving 3.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Enzalutamide for the Treatment of Androgen Receptor–Expressing Triple-Negative Breast Cancer

2018 348 citations Catherine M. Kelly, Maureen Trudeau et al. Journal of Clinical Oncology profile →
Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advanced breast cancer: NeoTRIP Michelangelo randomized study

2022 204 citations Luca Gianni, Chiun‐Sheng Huang et al. Annals of Oncology profile →

Peers

Countries citing papers authored by Catherine M. Kelly

Since Specialization

Citations

This map shows the geographic impact of Catherine M. Kelly's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Catherine M. Kelly with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Catherine M. Kelly more than expected).

Fields of papers citing papers by Catherine M. Kelly

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Catherine M. Kelly. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Catherine M. Kelly. The network helps show where Catherine M. Kelly may publish in the future.

Co-authorship network of co-authors of Catherine M. Kelly

This figure shows the co-authorship network connecting the top 25 collaborators of Catherine M. Kelly. A scholar is included among the top collaborators of Catherine M. Kelly based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Catherine M. Kelly. Catherine M. Kelly is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Refining source-specific lung cancer risk assessment from PM2.5-bound PAHs: Integrating component-based potency factors and machine learning in Ningbo, China 2025 ·Ecotoxicology and Environmental Safety ·(unknown),Ke Chen,(unknown),Catherine M. Kelly,Dongsheng Ji,Hang Xiao,Lei Tong,Zongshuang Wang,Jun He	2
2	Multimodal, Technology-Assisted Intervention for the Management of Menopause after Cancer Improves Cancer-Related Quality of Life—Results from the Menopause after Cancer (Mac) Study 2024 ·Cancers ·(unknown),Yvonne O’Meara,(unknown),(unknown),(unknown),(unknown),Marie Galligan,Michaela J. Higgins,Alasdair L. Henry,Catherine M. Kelly,Janice M. Walshe,Martha Hickey,Donal J. Brennan	0
3	LBA19 Event-free survival (EFS) analysis of neoadjuvant taxane/carboplatin with or without atezolizumab followed by an adjuvant anthracycline regimen in high-risk triple negative breast cancer (TNBC): NeoTRIP Michelangelo randomized study 2023 ·Annals of Oncology ·Luca Gianni,Chiun‐Sheng Huang,Daniel Egle,Begoña Bermejo,Claudio Zamagni,Marc Thill,A. Antón Torres,Giampaolo Bianchini,(unknown),Stefania Russo,Eva Ciruelos,Richard Greil,Semiglazov Vf,Marco Colleoni,Catherine M. Kelly,Gabriella Mariani,Lucia Del Mastro,(unknown),Hoda Ali,Giuseppe Viale	10
4	Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advanced breast cancer: NeoTRIP Michelangelo randomized studybreakdown → 2022 ·Annals of Oncology ·Luca Gianni,Chiun‐Sheng Huang,Daniel Egle,Begoña Bermejo,C. Zamagni,Marc Thill,A. Antón,Stefania Zambelli,Giampaolo Bianchini,Salvatore Russo,Eva Ciruelos,Richard Greil,Semiglazov Vf,Marco Colleoni,Catherine M. Kelly,Gabriella Mariani,Lucia Del Mastro,(unknown),Pinuccia Valagussa,Giuseppe Viale	204
5	Using menopausal hormone therapy after a cancer diagnosis in Ireland 2022 ·Irish Journal of Medical Science (1971 -) ·(unknown),Yvonne O’Meara,(unknown),(unknown),Catherine M. Kelly,Janice M. Walshe,(unknown),Martha Hickey,Donal J. Brennan	7
6	The menopause after cancer study (MACS) - A multimodal technology assisted intervention for the management of menopausal symptoms after cancer – Trial protocol of a phase II study 2021 ·Contemporary Clinical Trials Communications ·(unknown),Yvonne O’Meara,(unknown),(unknown),Catherine M. Kelly,Janice M. Walshe,Michelle Peate,Martha Hickey,Donal J. Brennan	2
7	Real-world analysis of clinical and economic impact of 21-gene recurrence score (RS) testing in early-stage breast cancer (ESBC) in Ireland 2021 ·Breast Cancer Research and Treatment ·(unknown),(unknown),(unknown),(unknown),(unknown),Denis Evoy,James Geraghty,R S Prichard,Jane Rothwell,Damian McCartan,E. McDermott,Maccon Keane,Michael J. Kennedy,Séamus O’Reilly,(unknown),John Crown,Lillian M. Smyth,Catherine M. Kelly,Cecily Quinn,Janice M. Walshe	6
8	Where youth matters—clinicopathologic characteristics and emerging trends in treatment and outcomes in young Irish women with breast cancer 2018 ·Irish Journal of Medical Science (1971 -) ·Megan Greally,(unknown),(unknown),(unknown),(unknown),(unknown),Niamh Coleman,Cecily Quinn,Enda McDermott,Giuseppe Gullo,John Crown,Ruth Prichard,Catherine M. Kelly,Janice M. Walshe	4
9	FORWARD I: A phase 3 study to evaluate the safety and efficacy of mirvetuximab soravtansine (IMGN853) versus chemotherapy in adults with folate receptor alpha (FRa)-positive, platinum-resistant epithelial ovarian cancer, primary peritoneal cancer, or primary fallopian tube cancer 2017 ·Annals of Oncology ·Kathleen N. Moore,Ignace Vergote,Ana Oaknin,Nicoletta Colombo,Susana Banerjee,Amit M. Oza,Patricia Pautier,Catherine M. Kelly,Karim Malek,Michael J. Birrer	1
10	Deciphering and Targeting Oncogenic Mutations and Pathways in Breast Cancer 2016 ·The Oncologist ·Libero Santarpia,Giulia Bottai,Catherine M. Kelly,Balázs Győrffy,Borbála Székely,Lajos Pusztai	38
11	Vismodegib in the treatment of advanced BCC. 2014 ·PubMed ·(unknown),Tomás G. Lyons,Ian A. McDonald,(unknown),(unknown),(unknown),Catherine M. Kelly	4
12	Benefit risk assessment and update on the use of docetaxel in the management of breast cancer 2013 ·Cancer Management and Research ·Catherine M. Kelly,(unknown)	34
13	Using Multiple Targeted Therapies in Oncology: Considerations for Use, and Progress to Date in Breast Cancer 2013 ·Drugs ·Catherine M. Kelly,Aman U. Buzdar	12
14	Randomized Controlled Trial of a Computerized Decision Aid on Adjuvant Radioactive Iodine Treatment for Patients With Early-Stage Papillary Thyroid Cancer 2012 ·Journal of Clinical Oncology ·Anna M. Sawka,Sharon E. Straus,Lorne Rotstein,James D. Brierley,Richard Tsang,L. Sylvia,(unknown),Catherine M. Kelly,Afshan Zahedi,Jeremy L. Freeman,Philip Solomon,Jennifer Anderson,Kevin E. Thorpe,Amiram Gafni,Gary Rodin,David P. Goldstein	37
15	Coping with uncertainty: T1a,bN0M0 HER2-positive breast cancer, do we have a treatment threshold? 2011 ·Annals of Oncology ·Catherine M. Kelly,Kathleen I. Pritchard,Maureen Trudeau,Eleni Andreopoulou,Kenneth R. Hess,Lajos Pusztai	20
16	Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population based cohort study 2010 ·BMJ ·Catherine M. Kelly,David N. Juurlink,Tara Gomes,Minh Duong-Hua,K. I. Pritchard,Peter C. Austin,Lawrence Paszat	311
17	Utility of oncotype DX risk estimates in clinically intermediate risk hormone receptor‐positive, HER2‐normal, grade II, lymph node‐negative breast cancers 2010 ·Cancer ·Catherine M. Kelly,Savitri Krishnamurthy,Giampaolo Bianchini,Jennifer K. Litton,Ana M. Gonzalez‐Angulo,Gabriel N. Hortobágyi,Lajos Pusztai	80
18	A randomized controlled trial to measure the effectiveness of a sacral wedge in preventing postoperative back pain following trans‐urethral resection of the prostate (TURP) in lithotomy position 2004 ·Journal of Clinical Nursing ·(unknown),Robin Riley,Christine Beanland,Catherine M. Kelly,(unknown)	2
19	A novel amino-terminally glycated analogue of glucose-dependent insulinotropic polypeptide (GIP), with prolonged insulinotropic activity in type 2 diabetes mellitus 2002 ·Diabetes ·Lindsay,(unknown),Catherine M. Kelly,Finbarr O’Harte,Peter R. Flatt,(unknown)	9
20	Colitis X in the horse 1972 ·New Zealand Veterinary Journal ·Catherine M. Kelly	2

About Catherine M. Kelly

Catherine M. Kelly is a scholar working on Cancer Research, Oncology and Pulmonary and Respiratory Medicine, having authored 149 papers that have together received 3.6k indexed citations. Recurring topics across this work include Breast Cancer Treatment Studies (33 papers), Advanced Breast Cancer Therapies (28 papers) and HER2/EGFR in Cancer Research (28 papers). The work is most often cited by research in Cancer Research (1.1k citations), Oncology (1.8k citations) and Pulmonary and Respiratory Medicine (842 citations). Catherine M. Kelly has collaborated with scholars based in Ireland, United States and United Kingdom. Frequent co-authors include Lajos Pusztai, Melanie Smith, Giuseppe Viale, Minh Duong-Hua, David N. Juurlink, Tara Gomes, Lawrence Paszat, K. I. Pritchard, Peter C. Austin and Clifford A. Hudis. Their work appears in journals such as Journal of Clinical Oncology, Diabetes Care and JNCI Journal of the National Cancer Institute.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact